Advertisement

Thiolated Polymers: Pharmaceutical Tool in Nasal Drug Delivery of Proteins and Peptides

  • Ashish Jain
  • Pooja Hurkat
  • Anki Jain
  • Ankit Jain
  • Abhishek Jain
  • Sanjay K. JainEmail author
Article
  • 129 Downloads

Abstract

Although bioavailability of peptides administered through nasal route is still under 1% because of low membrane permeability, a short local residence time and a high metabolic turnover in the nasal epithelium but the richly supplied vascular nature of the nasal mucosa coupled with its high drug permeation makes the nasal route of administration attractive for many drugs including proteins and peptides. Thiolated polymers (thiomers) which are also recognized as mucoadhesive polymers, discovered so far, attach itself to mucus membrane by covalent and non-covalent binding such as electrostatic forces and physical mechanism. These new generation polymers are capable of forming covalent bonds. Thiomers are of two types firstly anionic thiolated polymers having carboxylic acid groups as anionic substructures and cationic thiomers are mainly based on chitosan. Thiomers are hydrophilic molecules exhibiting free thiol groups responsible for numerous qualities of well-established polymeric excipients such as poly(acrylic acid) and chitosan. Thiomers possess cohesive, mucoadhesive, enzyme inhibitory and permeation enhancing properties. Thiomers based microparticles, microspheres, nanoparticles and gels for nasal drug delivery systems have shown promosing potential. Thiomers matrix-tablets are found to be stable under all storage conditions. On the basis of various properties, thiomers represent a promising new generation of multifunctional polymer for protein delivery through nasal route.

Keywords

Thiomers Protein delivery Nasal delivery Carbopol-cysteine Mucoadhesion Chitosan 

Notes

Compliance with Ethical Standards

Conflict of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Human and Animal Rights

Manuscript does not report any results on human experimentation (institutional and national).

References

  1. Allison SD, Dong A, Carpenter JF (1996) Counteracting effects of thiocyanate and sucrose on chymotrypsinogen secondary structure and aggregation during freezing, drying, and rehydration. Biophys J 71:2022–2032Google Scholar
  2. Arora P, Sharma S, Garg S (2002) Permeability issues in nasal drug delivery. Drug Discov Today 7:967–975Google Scholar
  3. Aungst BJ, Saitoh H, Burcham DL, Huang SM, Mousa SA, Hussain MA (1996) Enhancement of the intestinal absorption of peptides and non-peptides. J Control Release 41:19–31Google Scholar
  4. Aydogmus Z, Sarakbi A, Kauffmann JM (2016) Determination of thiols and free thiol content in a protein with liquid chromatography coupled to amperometric detection at a silver based carbon paste electrode. Electroanalysis 28(11):2703–2708Google Scholar
  5. Barbarić M, Kralj M, Marjanović M, Husnjak I, Pavelić K, Filipović-Grcić J et al (2007) Synthesis and in vitro antitumor effect of diclofenac and fenoprofen thiolated and nonthiolated polyaspartamide-drug conjugates. Eur J Med Chem 42(1):20–29Google Scholar
  6. Bernkop-Schnürch A (1998) The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J Control Release 52:1–16Google Scholar
  7. Bernkop-Schnürch A, Clausen E (2002) Permeability of peptides: strategies to improve the mucosal permeability of peptide drugs. Med Chem 2:295–305Google Scholar
  8. Bernkop-Schnürch A, Fragner R (1996) Investigations into the diffusion behaviour of polypeptides in native intestinal mucus with regard to their peroral administration. Pharm Sci 2:361–363Google Scholar
  9. Bernkop-Schnürch A, Thaler SC (2000) Polycarbophil-cysteine conjugates as platforms for oral polypeptide delivery systems. J Pharm Sci 89:901–909Google Scholar
  10. Bernkop-Schnürch A, Walker G (2001) Multifunctional matrices for oral peptide delivery. Crit Rev Ther Drug Carr Syst 18:459–501Google Scholar
  11. Bernkop-Schnürch A, Brandt UM, Clausen AE (1999a) Synthesis and in vitro evaluation of chitosan-cysteine conjugates. Sci Pharm 67:196–208Google Scholar
  12. Bernkop-Schnürch A, Schwarz V, Steinger S (1999b) Polymers with thiol groups: a new generation of mucoadhesive polymers? Pharm Res 16:876–881Google Scholar
  13. Bernkop-Schnürch A, Clausen AE, Hnatyszyn M (2001a) Thiolated polymers: synthesis and in vitro evaluation of polymer-cysteamine conjugates. Int J Pharm 226:185–194Google Scholar
  14. Bernkop-Schnürch A, Zarti H, Walker GF (2001b) Thiolation of polycarbophil enhances its inhibition of soluble and intestinal brush border membrane bound aminopeptidase. N J Pharm Sci 90:1907–1914Google Scholar
  15. Bernkop-Schnürch A, Hornof MD, Kast CE, Langoth N (2002) Thiolated polymers: stability of thiol moieties under different storage conditions. Sci Pharm 70:331–339Google Scholar
  16. Bernkop-Schnürch A, Kast CE, Guggi D (2003a) Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: thiomer/GSH systems. J Control Release 93:95–103Google Scholar
  17. Bernkop-Schnürch A, Egger C, Elhassan IM, Krauland AH (2003b) Preparation and in vitro characterization of poly(acrylic acid)-cysteine microparticles. J Control Release 93:29–38Google Scholar
  18. Bernkop-Schnürch A, Hornof M, Zoidl T (2003c) Thiolated polymers—thiomers: synthesis and in vitro evaluation of chitosan–2-iminothiolane conjugates. Int J Pharm 260(2):229–237Google Scholar
  19. Bernkop-Schnürch A, Leitner VM, Moser V (2004a) Synthesis and in vitro characterisation of a poly(acrylic acid)–homocysteine conjugate. Drug Dev Ind Pharm 30:1–8Google Scholar
  20. Bernkop-Schnürch A, Krauland AH, Leitner VM, Palmberger T (2004b) Thiomers: potential excipients for non-invasive peptide delivery systems. Eur J Pharm Biopharm 58:253–263Google Scholar
  21. Bernkop-Schnürch A, Obermair K, Greimel A, Palmberger TF (2006) In vitro evaluation of the potential of thiomers for the nasal administration of Leu-enkephalin. Amino Acids 30(4):417–423Google Scholar
  22. Biswas A, Joo K, Liu J, Zhao M, Fan G, Wang P, Gu Z, Tang Y (2011) Endoprotease-mediated intracellular protein delivery using nanocapsules. ACS Nano 5(2):1385–1394Google Scholar
  23. Calceti P, Salmaso S, Walker G, Bernkop-Schnürch A (2004) Development and in vivo evaluation of an oral insulin–PEG delivery system. Eur J Pharm Sci 22:315–323Google Scholar
  24. Cevc G (1996) Transferosomes, liposomes and other liquid suspension on the skin: permeation enhancement vesicle penetration and transdermal drug delivery. Crit Rev Ther Drug Carr Syst 13:257–388Google Scholar
  25. Chen XJ, Zhu JB, Wang GJ, Zhou MX, Xin FM, Zhang N et al (2002) Hypoglycemic efficacy of pulmonary delivered insulin dry powder aerosol in rats. Acta Pharmacol Sin 23:467–470Google Scholar
  26. Chiou GC, Li BH (1993) Chronic systemic delivery of insulin through the ocular route. J Ocul Pharmacol 9:85–90Google Scholar
  27. Coupe AJ, Davis SS, Wilding IR (1991) Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res 8:360–364Google Scholar
  28. Cuifang C (2007) Biodegradable polymer micro- and nanoparticles as protein delivery systems: influence of microparticle morphology and improvement of protein loading capacity of nanoparticles. DissertationGoogle Scholar
  29. Desai TR, Hancock REW, Finlay WH (2002) A facile method of delivery of liposomes by nebulization. J Control Release 84:69–78Google Scholar
  30. Deutel B, Laffleur F, Palmberger T (2016) In vitro characterization of insulin containing thiomeric microparticles as nasal drug delivery system. Eur J Pharm Sci 81(1):157–161Google Scholar
  31. Edsman K, Carlfors J, Petersson R (1998) Rheological evaluation of poloxamer as an in situ gel for ophthalmic use. Eur J Pharm Sci 6:105–112Google Scholar
  32. Gioia SD, Trapani A, Mandracchia D, De GE, Cometa S, Mangini V et al (2015) Intranasal delivery of dopamine to the striatum using glycol chitosan/sulfobutylether-β-cyclodextrin based nanoparticles. Eur J Pharm Biopharm 94:180–193Google Scholar
  33. Giteau A, Venier-Julienne MC, Aubert-Pouessel A, Benoit JP (2008) Historical perspectives, how to achieve sustained and complete protein release from PLGA-based microparticles? Int J Pharm 350:14–26Google Scholar
  34. Gu Z, Biswas A, Zhao M, Tang Y (2011) Tailoring nanocarriers for intracellular protein delivery. Chem Soc Rev 40(7):3638–3655Google Scholar
  35. Guggi D, Kast CE, Bernkop-Schnürch A (2003a) In vivo evaluation of an oral salmon calcitonin-delivery system based on a thiolated chitosan carrier matrix. Pharm Res 20(12):1989–1994Google Scholar
  36. Guggi D, Krauland AH, Bernkop-Schnürch A (2003b) Systemic peptide delivery via the stomach: in vivo evaluation of an oral dosage form for salmon calcitonin. J Control Release 92(1–2):125–135Google Scholar
  37. Guggi D, Marschütz MK, Bernkop-Schnürch A (2004) Matrix tablets based on thiolated poly(acrylic acid): pH dependent variation in disintegration and mucoadhesion. Int J Pharm 274:97–105Google Scholar
  38. Hanif M, Zaman M, Qureshi S (2015) Thiomers: a blessing to evaluating era of pharmaceuticals. Int J Polym Sci 2015:1–9Google Scholar
  39. Hashimoto K, Tatsumi N (1989) Rapid isolation of human C reactive protein and serum amyloid P component. J Immunol Methods 20125(1–2):295–296Google Scholar
  40. Hinchcliffe M, Illum L (1999) Intranasal insulin delivery and therapy. Adv Drug Deliv Rev 35(2–3):199–234Google Scholar
  41. Illum L (1996) Nasal delivery. The use of animal models to predict performance in man. J Drug Target 3(6):427–442Google Scholar
  42. Illum L (1998) Chitosan and its use as a pharmaceutical excipient. Pharm Res 15(9):1326–1331Google Scholar
  43. Illum L (2003) Nasal drug delivery-possibilities, problems and solutions. J Control Release 87:187–198Google Scholar
  44. Jain A, Jain A, Gulbake A, Shilpi S, Hurkat P, Jain SK (2013) Peptide and protein delivery using new drug delivery systems critical reviews™ in therapeutic. Drug Carr Syst 30(4):293–329Google Scholar
  45. Johannson F, Hjertberg E, Eirefelt S, Tronde A, Hultkvist BU et al (2002) Mechanisms for absorption enhancement of inhaled insulin by sodium taurocholate. Eur J Pharm Sci 17:63–71Google Scholar
  46. Jorgensen L, Moeller EH, van deWeert M, Nielsen HM, Frokjaer S (2006) Preparing and evaluating delivery systems for proteins. Eur J Pharm Sci 29:174–182Google Scholar
  47. Kast CE, Bernkop-Schnürch A (2002) Influence of the molecular mass on the permeation enhancing effect of different poly(acrylates). STP Pharm Sci 12:351–356Google Scholar
  48. Krauland AH, Bernkop-Schnürch A (2004) Thiomers: development and in vitro evaluation of a peroral microparticulate peptide delivery system. Eur J Pharm Biopharm 57:181–187Google Scholar
  49. Krauland AH, Leitner VM, Grabovac V, Bernkop-Schnürch A (2006) In vivo evaluation of a nasal insulin delivery system based on thiolated chitosan. J Pharm Sci 95(11):2463–2472Google Scholar
  50. Lam XM, Duenas ET, Daugherty AL, Levin N, Cleland JL (2000) Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes. J Control Release 67:281–292Google Scholar
  51. Laursen T, Grandjean B, Jorgensen JO, Christiansen JS (1996) Bioavailability and bioactivity of three different doses of nasal growth hormone (GH) administered to GH-deficient patients: comparison withintravenous and subcutaneous administration. Eur J Endocrinol 135:309–315Google Scholar
  52. Lee V (1991) Peptide and protein drug delivery. In: Welling PG (ed) Pharmacokinetics: regulatory, industrial, academic perspectives drugs and the pharmaceutical sciences, 2nd edn. CRC Press, Boca Raton, pp 59–88Google Scholar
  53. Lehr CM (1996) From sticky stu! to sweet receptors achievements, limits and novel approaches to bioadhesion. Eur J Drug Metab Pharm 21:139–148Google Scholar
  54. Leitner VM, Walker GF, Bernkop-Schnu¨rch A (2003a) Thiolated polymers: evidence for the formation of disulphide bonds with mucus glycoproteins. Eur J Pharm Biopharm 56:207–214Google Scholar
  55. Leitner VM, Marschutz MK, Bernkop-Schnu¨rch A (2003b) Mucoadhesive and cohesive properties of poly(acrylic acid)–cysteine conjugates with regard to their molecular mass. Eur J Pharm Sci 18:89–96Google Scholar
  56. Leitner VM, Guggi D, Bernkop-Schnürch A (2004) Thiomers in noninvasive polypeptide delivery: in vitro and in vivo characterization of a polycarbophil-cysteine/glutathione gel formulation for human growth hormone. J Pharm Sci 93(7):1682–1691Google Scholar
  57. Mahajan H, sheikh H, gattani S, Nerkar P (2009) In situ gelling system based on thiolated gellan gum as new carrier for nasal administration of dimenhydrinate. Int J pharm Sci nanotech 2(2):544–550Google Scholar
  58. Menzel C, Jelkmann M, Laffleur F, Bernkop-Schnürch A (2017) Nasal drug delivery: design of a novel mucoadhesive and in situ gelling polymer. Int J Pharm 30(1–2):196–2002Google Scholar
  59. Millotti G, Vetter A, Leithner K, Sarti F, Bano GS, Augustijns P et al (2014) Development of thiolated poly(acrylic acid) microparticles for the nasal administration of exenatide. Drug Dev Ind Pharm 40(12):1677–1682Google Scholar
  60. Misra A (2002) Improved transnasal transport and brain uptake of tizanidine HCl loaded thiolated chitosan nanoparticles for alleviation of pain. J Pharm Sci 101(2):690–706Google Scholar
  61. Morishita M, Peppas NA (2006) Is the oral route possible for peptide and protein drug delivery? Drug Discov Today 11(19–20):905–910Google Scholar
  62. Nema T, Jain A, Jain A, Shilpi S, Gulbake A, Hurkat P, Jain SK (2013) Insulin delivery through nasal route using thiolated microspheres. Drug Deliv 20(5):210–215Google Scholar
  63. Netsomboon K, Partenhauser A, Rohrer J, Sündermann NE, Prüfert F, Suchaoin W et al (2016) Preactivated thiomers for intranasal delivery of apomorphine: in vitro and in vivo evaluation. Eur J Pharm Biopharm 109:35–42Google Scholar
  64. O’Hagan DT, Illum L (1990) Absorption of peptides and proteins from the respiratory tract and the potential for development of locally administered vaccine. Crit Rev Ther Drug Carr Syst 7(1):35–97Google Scholar
  65. Perrone M, Lopalco A, Lopedota A, Cutrignelli A, Laquintana V, Douglas J, Franco M, Liberati E, Russo V, Tongiani S, Denora N, Bernkop-Schnürch A (2017) Preactivated thiolated glycogen as mucoadhesive polymer for drug delivery. Eur J Pharm Biopharm 119:161–169Google Scholar
  66. Pringels E, Callens C, Vervaet C, Dumont F, Slegers G, Foreman P et al (2006) Influence of deposition and spray pattern of nasal powders on insulin bioavailability. Int J Pharm 310:1–7Google Scholar
  67. Ramaprasad YVR, Krishnaiah YSR, Satnarayana S (1996) Intranasal drug delivery systems. An overview. Indian J Pharm Sci 58:1–8Google Scholar
  68. Rozier A, Mazuel C, Grove J, Plazonnet B (1989) Gelrite: a novel, ionactivated, in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol. Int J Pharm 57:163–168Google Scholar
  69. Samuel AJ, Kulkarni M, Tambe R (2010) Thiomers: forms, features and formulations. J Chem Pharm Res 2(6):316–323Google Scholar
  70. Sarmento B (2010) Nanomedicines for delivery of therapeutic proteins and biopharmaceuticals. Ther Deliv 1(2):231–235Google Scholar
  71. Shahnaz G, Vetter A, Barthelmes J, Rahmat D, Laffleur F, Iqbal J et al (2012) Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization. Int J Pharm 428(1–2):164–170Google Scholar
  72. Singh D, Muzamil R, Singh SH, Mehra NK, Prakash A, Mishra N (2016) Pharmacological evaluation of nasal delivery of selegiline hydrochloride-loaded thiolated chitosan nanoparticles for the treatment of depression. Artif Cells Nanomed Biotechnol 44(3):865–877Google Scholar
  73. Sinha VR, Trehan A (2003) Biodegradable microspheres for protein delivery. J Control Release 90:261–280Google Scholar
  74. Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L (1999) Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 178:55–65Google Scholar
  75. Soane RJ, Hinchcliffe M, Davis SS, Illum L (2001) Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int J Pharm 217:183–191Google Scholar
  76. Soni V, Singh R, Srinivasan R, Jain SK (1998) Pulsatile insulin delivery through the ocular route. Drug Deliv 5:47–51Google Scholar
  77. Sreenivas SA, Pai KV (2008) Thiolated chitosans: novel polymers for mucoadhesive drug delivery—a review tropical. J Pharm Res 7(3):1077–1088Google Scholar
  78. Srinivasan R, Jain SK (1998) Insulin delivery through ocular route—II. Drug Deliv 5(1):53–55Google Scholar
  79. Sunena MD, Singh SK, Kumar A (2016) Development and characterization of zolmitriptan loaded thiolated chitosan nanoparticles for intranasal drug delivery. Pharm Innov J 5(7):19–23Google Scholar
  80. Synder GH, Reddy MK, Cennerazzo MJ, Field D (1983) Use of local electrostatic environments of cysteines to enhance formation of desired species in a revesible disulfide exchange reaction. Biochim Biophys Acta 749:219–226Google Scholar
  81. Ugwoke MI, Verbeke N, Kinget R (2001) The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol 53:3–21Google Scholar
  82. Vetter A, Martien R, Bernkop-Schnürch A (2010) Thiolated polycarbophil as an adjuvant for permeation enhancement in nasal delivery of antisense oligonucleotides. J Pharm Sci 99(3):1427–1439Google Scholar
  83. Veuillez F, Kalia YN, Jacques Y, Deshusses J, Buri P (2001) Factors and strategies for improving buccal absorption of peptides. Eur J Pharm Biopharm 51:93–109Google Scholar
  84. Vila A, Sanchez A, Tobio M, Calvo P, Alonso MJ (2002) Design of biodegradable particles for protein delivery. J Control Release 78:15–24Google Scholar
  85. Wang W (1999) Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 185:129–188Google Scholar
  86. Wang X, Zheng C, Wu Z, Teng D, Zhang X, Wang Z et al (2009) Chitosan-NAC nanoparticles as a vehicle for nasal absorption enhancement of insulin. J Biomed Mater Res B 88(1):150–161Google Scholar
  87. Yamamoto A, Luo AM, Dodda-Kashi S, Lee VH (1989) The ocular route for systemic insulin delivery in the albino rabbit. J Pharmacol Exp Ther 249:249–255Google Scholar
  88. Yang J, Cleland JL (1997) Factors affecting the in vitro release of recombinant human interferon-gamma (rhIFN-gamma) from PLGA microspheres. J Pharm Sci 86:908–914Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Ashish Jain
    • 1
  • Pooja Hurkat
    • 1
  • Anki Jain
    • 1
  • Ankit Jain
    • 3
  • Abhishek Jain
    • 2
  • Sanjay K. Jain
    • 1
    Email author
  1. 1.Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical SciencesDr. H. S. Gour VishwavidyalayaSagarIndia
  2. 2.Sagar Institute of Pharmaceutical SciencesSagarIndia
  3. 3.Institute of Pharmaceutical ResearchGLA UniversityMathuraIndia

Personalised recommendations